Novartis (NVS) raised its full-year profit outlook thanks to strong demand for some of its key drugs. Novartis CEO Vas Narasimhan joins Market Catalysts to discuss the company's growth drivers ...

Novartis (NYSE:NVS) CEO Vas Narasimhan said the company has built up its U.S. inventories to help mitigate the impact of tariffs this year. During a CNBC interview, Narasimhan emphasized the ...

Novartis CEO Vas Narasimhan weighs in on the impact of the new U.S. administration and artificial intelligence on the pharmaceutical industry, as well as the possibility of further acquisitions.

Vas Narasimhan, the CEO of Novartis, discusses the Swiss pharmaceutical company's first-quarter earnings. MAGA divided as Trump turns on Putin 'Trash' found deep inside a Mexican cave turns out to ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant having nothing to fear ...

Novartis, after slimming down, boosts growth projection through the end of the decade By Kevin Dunleavy Nov 21, 2024 11:57am Novartis Cosentyx Vas Narasimhan Entresto ...

Novartis CEO Vas Narasimhan outlined projections for the company's future at the 2025 JP Morgan Healthcare conference in San Francisco on 14 January. Novartis, he said, expects peak sales of over ...

Novartis’ overhaul has hit its R&D group, and that’s putting an increased emphasis on the key expansions of cancer drugs Kisqali and Pluvicto.